p38 MAPK inhibitors suppress biomarkers of hypertension end-organ damage, osteopontin and plasminogen activator inhibitor-1

References

• Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, Willette RN. p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Current Opinions in Investigational Drugs 2003; 4: 1059–1064
   PubMedGoogle Scholar
• Behr TM, Nerurkar SS, Nelson AH, Coatney RW, Woods TN, Sulpizio A, Chandra S, Brooks DP, Kumar S, Lee JC, Ohlstein EH, Angermann CE, Adams JL, Sisko J, Sackner-Bernstein JD, Willette RN. Hypertensive end-organ damage and premature mortality are p38 mitogen-activated protein kinase-dependent in a rat model of cardiac hypertrophy and dysfunction. Circulation 2001; 104: 1292–1298
   PubMed Web of Science ®Google Scholar
• Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. Journal of Biological Chemistry 2002; 277(46)44485–44496
   PubMed Web of Science ®Google Scholar
• Brown GE, Stewart MQ, Bissonnette SA, Elia AEH, Wilker E, Yaffe MB. Distinct ligand-dependent roles for p38 MAPK in priming and activation of the neutrophil NADPH oxidase. Journal of Biological Chemistry 2004; 279: 27059–27068
   PubMed Web of Science ®Google Scholar
• Campos AH, Zhao Y, Pollman MJ, Gibbons GH. DNA microarray profiling to identify angiotensin-responsive genes in vascular smooth muscle cells — potential mediators of vascular disease. Circulation Research 2003; 92: 111–118
   PubMed Web of Science ®Google Scholar
• Chen HC, Bouchie JL, Perez AS, Clermont AC, Izumo S, Hampe J, Feener DP. Role of the angiotensin AT(1) receptor in rat aortic and cardiac PAI-1 gene expression. Arteriosclerosis, Thrombosis and Vascular Biology 2000; 20: 2297–2302
   PubMed Web of Science ®Google Scholar
• Datta PK, Blake MC, Moses HL. Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta-induced physical and functional interactions between Smads and Sp1. Journal of Biological Chemistry 2000; 275(51)40014–40019
   PubMed Web of Science ®Google Scholar
• Deblois D, Lombardi DM, Su EJ, Clowes AW, Schwartz SM, Giachelli CM. Angiotensin II induction of Osteopontin expression and DNA replication in rat arteries. Hypertension 1996; 28(6)1055–1063
   PubMed Web of Science ®Google Scholar
• Fisher GJ, Talwar HS, Lin JY, Lin PP, McPhillips F, Wang ZQ, Li XY, Wan YS, Kang SW, Vorhees JJ. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. Journal of Clinical Investigation 1998; 101(6)1432–1440
   PubMed Web of Science ®Google Scholar
• Gauer S, Hartner A, Hauser IA, Fierlbeck W, Eberhardt W, Geiger H. Differential regulation of osteopontin expression in the clipped and nonclipped kidney of two-kidney, one-clip hypertensive rats. American Journal of Hypertension 2003; 16(3)214–222
   PubMed Web of Science ®Google Scholar
• Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney International 2002; 62: 237–244
   PubMed Web of Science ®Google Scholar
• Horrevoets AJG. Plasminogen activator inhibitor 1 (PAI-1): in vitro activities and clinical relevance. British Journal of Haematology 2004; 125: 12–23
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wan Y. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45: 198–202
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J. A unifying pathway for essential hypertension. American Journal of Hypertension 2005; 18: 431–440
   PubMed Web of Science ®Google Scholar
• Ju H, Behm DJ, Nerurkar SS, Eybye ME, Haimbach RE, Olzinski AR, Douglas SA, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension. Journal of Pharmacology and Experimental Therapeutics 2003; 307: 932–938
   PubMed Web of Science ®Google Scholar
• Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. Journal of Thrombosis and Haemostasis 2003; 1: 1575–1579
   PubMed Web of Science ®Google Scholar
• Junaid A, Amara FM. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 2004; 44(2)136–146
   PubMed Web of Science ®Google Scholar
• Kaikita K, Fogo AB, Ma LJ, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001; 104: 839–844
   PubMed Web of Science ®Google Scholar
• Kasza A, Kiss DL, Gopalan S. Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes. Journal of Neurochemistry 2002; 83(3)696–703
   PubMed Web of Science ®Google Scholar
• Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 Mitogen-activated protein kinase inhibitor-mechanisms and therapeutic potentials. Pharmacology and Therapeutics 1999; 82(2–3)389–397
   PubMed Web of Science ®Google Scholar
• Lenhard SC, Nerurkar SS, Schaeffer TR, Mirabile RC, Boyce RW, Adams DF, Jucker BM, Willette RN. p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 2. Improved renal function as assessed by dynamic contrast-enhanced magnetic resonance imaging. Journal of Pharmacology and Experimental Therapeutics 2003; 307: 939–946
   PubMed Web of Science ®Google Scholar
• Luft FC, Mervaala E, Muller DN, Gross V, Schmidt F, Park JK, Schmitz C, Lippoldt A, Breu V, Dechend R, Dragun D, Schneider W, Ganten D, Haller H. Hypertension-induced end-organ damage: a new transgenic approach to an old problem. Hypertension 1999; 33: 212–218
   PubMed Web of Science ®Google Scholar
• Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. Journal of Biological Chemistry 2001; 276(17)13664–13674
   PubMed Web of Science ®Google Scholar
• Mathieson PW. The cellular basis of albuminuria. Clinical Science 2004; 107: 533–538
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin — a molecule for all seasons. Quarterly Journal of Medicine 2002; 95: 3–13
   Google Scholar
• Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33: 389–395
   PubMed Web of Science ®Google Scholar
• National Institutes of Health (NIH). 1996. Guide for care and use of laboratory animals. Publication No. 85–23. National Research Council. Washington, DC..
   Google Scholar
• Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlof B, Ibsen H, Devereux RB. Albuminuria predicts cardiovascular events independently of left ventricular mass in hypertension: a LIFE substudy. Journal of Human Hypertension 2004; 18: 453–459
   PubMed Web of Science ®Google Scholar
• Olzinski AR, McCafferty TA, Zhao SQ, Behm DJ, Eybye ME, Maniscalco K, Bentley R, Frazier KS, Milliner CM, Mirabile RC, Coatney RW, Willette RN. Hypertensive target organ damage is attenuated by a p38 MAPK inhibitor: role of systemic blood pressure and endothelial protection. Cardiovascular Research 2005; 66: 170–178
   PubMed Web of Science ®Google Scholar
• Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. American Journal of Hypertension 2002; 15: 683–690
   PubMed Web of Science ®Google Scholar
• Tanos T, Marinissen MJ, Leskow FC, Hochbaum D, Martinetto H, Gutkind JS, Coso OA. Phosphorylation of c-fos by members of the p38 MAPK family — role in the AP-1 response to UV light. Journal of Biological Chemistry 2005; 280(19)18842–18852
   PubMed Web of Science ®Google Scholar
• Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovascular Disorders 2002; 2: 3
   PubMedGoogle Scholar
• Thomas SE, Lombardi D, Giachelli C, Bohle A, Johnson RJ. Osteopontin expression, tubulointerstitial disease, and essential hypertension. American Journal of Hypertension 1998; 11: 954–961
   PubMed Web of Science ®Google Scholar
• Vulin AI, Stanley FM. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. Journal of Biological Chemistry 2004; 279(24)25172–25178
   PubMed Web of Science ®Google Scholar
• Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Annals of Internal Medicine 2003; 139: 901–906
   PubMed Web of Science ®Google Scholar
• Wang D, Yamamoto S, Hijiya N, Benveniste EN. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA–protein interactions. Oncogene 2000; 19(50)5801–5809
   PubMed Web of Science ®Google Scholar